Major market regulators and international standards bodies have upped the ante for control of the end-to-end pharmaceutical supply chain, starting with the ingredients.
In 2015, the EU Commission published Good Distribution Practices for Active Pharmaceutical Ingredients, not just Good Manufacturing Practices.
